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ABSTRACT
Background In patients with stable angina (SA), the 
clinical benefits of percutaneous coronary intervention 
(PCI) reside almost exclusively within the realm of 
symptomatic improvement rather than improvement in 
hard clinical endpoints. The benefits of PCI should always 
be balanced against its potential short- term and long- 
term risks. Common among these risks is the presence 
of anaemia and its interaction with poor clinical outcomes 
and increased morbidity; this study aims to elucidate the 
impact of anaemia on long- term clinical outcomes of this 
patient group.
Methods From Danish national registries, we identified 
patients with SA treated with PCI who had a haemoglobin 
measurement maximum of 90 days prior to PCI procedure. 
Anaemia was defined as haemoglobin <130 and <120 g/L 
in men and women, respectively. Follow- up was up to 3 
years after PCI, and Cox regression was used to estimate 
HRs with 95% CIs of hospitalisation due to bleeding, 
acute coronary syndrome (ACS) and all- cause mortality 
in patients with anaemia compared with patients without 
anaemia.
Results Of 2837 included patients, 14.6% had anaemia 
prior to PCI. During follow- up, 93 patients (3.3%) had 
a bleeding episode, which was higher in patients with 
anaemia (5.8%) compared with patients without anaemia 
(2.8%). A total of 213 patients (7.5%) developed ACS, 
which was higher in patients with anaemia (10.6%) 
compared with patients without anaemia (7.0%). 
Furthermore, 185 patients (6.5%) died, with a mortality 
rate of 18.1% in patients with anaemia compared with 
4.5% in patients without anaemia. In multivariable 
analyses, anaemia was associated with a significantly 
increased risk of bleeding (HR 1.69; 95% CI 1.04 to 2.73; 
P 0.033), ACS (HR 1.47; 95% CI 1.04 to 2.10; P 0.031) 
and all- cause mortality (HR 2.41; 95% CI 1.73 to 3.30; P 
<0.001).
Conclusion Anaemia in patients with SA was significantly 
associated with bleeding, ACS and all- cause mortality 
following PCI.
INTRODUCTION
The optimal intervention strategy for stable 
angina (SA) remains controversial.1 2 In these 
patients, no survival benefit for percutaneous 
coronary intervention (PCI) has been shown 
when compared with medical therapy.3–7Pre-
vious studies have indicated better symptom 
relief and improved quality of life (QoL) 
for PCI- treated patients relative to medically 
treated patients.8 However, this may be a 
short- term benefit only,8 and PCI carries an 
additional risk of postprocedural bleeding, 
driven by the need for dual antiplatelet 
therapy or dual antiplatelet therapy together 
with oral anticoagulant therapy in an increas-
ingly ageing population.9 10
Key questions
What is already known about this subject?
 ► Given evidence suggesting no survival benefit of 
percutaneous coronary intervention (PCI) in patients 
with stable angina, and PCI carries an additional risk 
of postprocedural bleeding.
 ► Baseline anaemia is recognised as an independent 
risk factor for bleeding and has previously been 
found as a predictor of in- hospital bleeding follow-
ing PCI.
What does this study add?
 ► This study confirmed anaemia as an independent 
predictor of bleeding, acute coronary syndrome and 
mortality in the longer term, in patients with SA un-
dergoing PCI.
How might this impact on clinical practice?
 ► Predicting a considerable bleeding risk prior to elec-
tive or ad hoc PCI by the means of a haemoglobin 
measurement is of great value and should modify 
our treatment strategies to more frequent use of 
medical therapy in these high- risk patients with rel-
atively small reductions in haemoglobin.
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Considering the postprocedural bleeding risk asso-
ciated with PCI and that patients with SA often receive 
dual antiplatelet therapy and/or oral anticoagulant 
therapy, predicting a considerable bleeding risk prior 
to decision- making is of great value. Anaemia is already 
acknowledged as an independent risk factor for bleeding 
in the treatment of acute coronary syndrome (ACS) with 
PCI,11–16 thus assessing the haemoglobin status in patients 
with SA by means of risk assessment prior to PCI could 
be substantial. In addition, a haemoglobin level may also 
be associated with post- PCI ACS and mortality potentially 
driven by early cessation of dual antiplatelet therapy and 
blood/platelet transfusions.
Therefore, using nationwide register- based data on 
PCI procedures and haemoglobin levels from selected 
Danish regions, we studied bleeding requiring hospital-
isation, ACS and all- cause mortality in relation to haemo-
globin levels among patients with SA undergoing PCI in 
Denmark during 2004–2012.
METHODS
Data source
All residents in Denmark have a personal, unique and 
permanent civil registration number that enables indi-
vidual linkage of personal data from all nationwide 
administrative registers. Data regarding sex and age were 
obtained from the Danish Civil Registration System.17 
Survival status was gathered from the Danish Register of 
Causes of Death.18 Admission dates, procedure codes, 
operation codes, operation dates, hospital discharge 
dates and discharge diagnoses were collected from the 
Danish National Patient Register, which contains all 
hospital admissions in Denmark since 1978.19 Hospital 
discharge diagnosis is classified according to the WHO 
International Classification of Diseases (ICD). The 
10th revision (ICD-10) has been applied from 1994 and 
onwards. The Danish National Prescription Registry 
includes all dispensed prescriptions from all Danish 
pharmacies since 1995 based on the Anatomical Thera-
peutic Chemical codes, and information about the phar-
macotherapy of each patient was collected from here.20 
As the healthcare system is state financed and the state 
partly reimburses drug costs, all Danish pharmacies are 
required by law to register all dispensed drug prescrip-
tions, providing a valid and accurate register. From three 
regions in Denmark, with a source population of approx-
imately 1.2 million inhabitants, blood test results were 
obtained from electronic registers of laboratory data.
Study population
The study population consists of Danish patients with a 
first- time stable coronary artery disease diagnosis between 
2004 and 2012, either from a hospital or an ambulatory 
outpatient contact (online supplemental appendix 1). 
In addition, patients were required to have been treated 
with PCI following the stable coronary artery disease diag-
nosis (online supplemental appendix 2). Patients were 
excluded if they did not have a haemoglobin measure-
ment on the day of PCI or maximum 90 days before. As 
information about the extent of antithrombotic therapy 
is of great importance for the study, baseline was set to be 
7 days following the day of PCI, giving patients enough 
time to redeem a prescription for the medication after 
the procedure. Patients with an ACS diagnosis, PCI proce-
dure or coronary artery bypass grafting procedure prior 
to the stable coronary artery disease diagnosis or PCI for 
ACS were excluded from the study population. Patients 
who were bleeding, suffering from ACS or died in the 
period between PCI until baseline (+7 days from PCI) 
were also excluded, as we demanded a 7- day period for 
patients to redeem prescriptions for relevant antithrom-
botic therapies post- PCI as mentioned above. We also 
excluded patients without a creatinine measurement on 
the day of PCI or maximum 90 days before. Thus, no 
patients in the study were missing baseline data. A flow 
chart is presented in online supplemental appendix 3.
Comorbidities and concomitant pharmacotherapy
Clinically relevant comorbidities and concomitant phar-
macotherapy were identified and used as covariates in 
the analysis. Patients were considered having a specific 
comorbidity if the diagnosis was registered up to 10 years 
prior to the day of PCI. Comorbidities were identified 
from the Danish National Patient Register based on 
ICD-10 codes, and included diagnoses of heart failure, 
peripheral vascular disease, cerebral vascular disease, 
chronic obstructive pulmonary disease (COPD), peptic 
ulcer, hypertension, diabetes, cancer and atrial fibril-
lation. Diabetes and COPD are usually managed in 
primary care, and a diagnosis is therefore not necessarily 
registered. Thus, patients in the study were also consid-
ered to be suffering from diabetes or COPD if at least 
one prescription of antidiabetic medication or inhaled 
anticholinergic, beta adrenergic, or the combination of 
anticholinergic, beta adrenergic and/or corticosteroid 
inhalation medication had been dispensed at maximum 
of 180 days prior to PCI. Using ICD-10 codes, previous 
episodes of bleeding requiring hospitalisation were 
also identified up to 2 years prior to PCI. Renal status 
was evaluated by estimated glomerular filtration rate 
(eGFR). A creatinine measurement on the day of PCI 
or maximum 90 days before was used in the Chronic 
Kidney Disease Epidemiology Collaboration creati-
nine equation to calculate eGFR. Patients were consid-
ered having renal insufficiency with an eGFR <30 mL/
min/1.73 m2. In addition, we identified patients treated 
with antithrombotic medication within 180+7 days prior 
to baseline, and divided them into four groups (none, 
single, dual or triple therapy) depending on the number 
of different antithrombotic drugs they were treated with. 
The antithrombotic medication included in the study 
was acetylsalicylic acid, heparin, non- vitamin K antago-
nist oral anticoagulants, platelet inhibitors and vitamin 
K antagonist (online supplemental appendices 1 and 4).
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Definition of anaemia
Baseline demographics and clinical characteristics were 
compared by dividing all patients into two groups based 
on haemoglobin levels. Patients with a blood haemo-
globin concentration less than 8.1 mmol/L (corre-
sponding to 130 g/L) in men and less than 7.5 mmol/L 
(corresponding to 120 g/L) in women were classified as 
having anaemia. Both groups were according to the cut- 
off values defined by the WHO.21 The final study popu-
lation combined the classification of men and women as 
anaemic or non- anaemic.
Outcomes
The primary outcome of interest was hospitalisation 
due to cerebral, gastrointestinal or urogenital bleeding 
in a follow- up period of 3 years. Secondary outcomes 
were ACS, including fatal ACS, and all- cause mortality. 
Bleeding and ACS were identified from the Danish 
National Patient Register based on ICD-10 codes (online 
supplemental appendix 1). The study population was 
followed from baseline until bleeding, ACS, or mortality, 
or until patients were censored 3 years after baseline, 
depending on whichever came first.
Statistical analysis
Categorical variables were presented as counts and 
percentages, and continuous variables as median with 
25–75 percentiles. Cumulative incidence of bleeding 
and ACS was estimated using the Aalen- Johansen esti-
mator, treating mortality as a competing risk. Survival was 
depicted using Kaplan- Meier estimates. A Cox propor-
tional hazards regression model was used to determine 
the association between anaemia and bleeding, ACS 
and all- cause mortality. From these models, HRs with 
95% CIs were reported. A two- sided p value below 0.05 
was considered statistically significant. The propor-
tional hazard assumption was tested for all regression 
models and was fulfilled. In addition, the assumption 
of linearity was tested for age, and because of lack of 
linearity, age was included in the regression model as 
four groups (<60 years, 60–69 years, 70–79 years, >79 
years). We tested for interactions using a log likelihood 
ratio test. A two- sided p value below 0.01 was considered 
statistically significant, and no interactions were found. 
In the multivariable analysis of bleeding we adjusted for 
sex, age groups, renal insufficiency, peptic ulcer, cancer, 
hypertension and antithrombotic therapy. The adjusted 
analysis of all- cause mortality included the following 
covariates: sex, age groups, renal insufficiency, heart 
failure, peripheral vascular disease, cerebral vascular 
disease, COPD, hypertension, diabetes, cancer, peptic 
ulcer and antithrombotic therapy. Multivariable analysis 
of ACS included the same covariates as the analysis of 
all- cause mortality except peptic ulcer. All data manage-
ment and analyses were performed using SAS (V.9.4, 
SAS Institute) and R statistics V.3.5.0 (R Development 
Core Team).22
RESULTS
Baseline characteristics
The study population consisted of 2837 patients with 
SA treated with PCI who had an available haemoglobin 
measurement (online supplemental appendix 3). Base-
line characteristics of these patients were mainly compa-
rable to baseline characteristics of the excluded patients 
without a haemoglobin measurement (online supple-
mental appendix 6).
The baseline characteristics of the study population are 
presented in table 1. Of the 2837 patients, 414 (14.6%) 
were anaemic. The distribution of haemoglobin levels 
in the population is presented in online supplemental 
appendix 7. The overall population was characterised 
by advanced age (median: 65.5; 25–75 percentiles: 58.7–
72.7) and the majority of patients were male (71.4%). 
Compared with patients without anaemia, patients 
with anaemia were older (no anaemia, median: 64.9; 
anaemia, median: 70.8) and had a higher comorbidity 
Table 1 Baseline characteristics
No anaemia 
(n=2423)
Anaemia
(n=414) P value
Haemoglobin
  Mean (SD) 8.93 (0.66) 7.26 (0.66) <0.0001
Sex
  Female 684 (28.2%) 126 (30.4%)
  Male 1739 (71.8%) 288 (69.6%) 0.3901
Age
  Median (p25–p75) 64.9 (58.3, 71.8) 70.8 (62.3, 78.0) <0.0001
Heart failure 225 (9.3%) 95 (22.9%) <0.0001
Peripheral vascular 
disease
178 (7.3%) 56 (13.5%) <0.0001
Cerebral vascular 
disease
167 (6.9%) 51 (12.3%) 0.0002
Chronic obstructive 
pulmonary disease
249 (10.3%) 68 (16.4%) 0.0003
Peptic ulcer 126 (5.2%) 34 (8.2%) 0.0193
Cancer 182 (7.5%) 46 (11.1%) 0.0168
Atrial fibrillation 187 (7.7%) 57 (13.8%) <0.0001
Hypertension 915 (37.8%) 202 (48.8%) 0.0011
Diabetes 371 (15.3%) 111 (26.8%) <0.0001
Renal insufficiency 21 (0.9%) 35 (8.5%) <0.0001
Previous bleeding 8 (0.3%) 10 (2.4%) <0.0001
Antithrombotic 
therapy
  None 92 (3.8%) 26 (6.3%)
  Single 546 (22.5%) 112 (27.1%)
  Dual 1686 (69.6%) 247 (59.7%)
  Triple 99 (4.1%) 29 (7.0%) 0.0002
Data are presented as number of patients (column percentage) 
in all parameters except for age and haemoglobin. Data are in 
the age parameter presented as median and the 25th and 75th 
percentiles, and in the haemoglobin parameter as mean and SD.
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burden. The baseline use of antithrombotic agents was 
as follows: 118 (4.2%) patients were not treated with 
antithrombotic medicine, 658 (23.2%) patients received 
single antithrombotic therapy, 1933 (68.1%) patients 
received dual antithrombotic therapy and 128 (4.5%) 
patients received triple antithrombotic therapy. The 
components of dual antithrombotic therapy were in 1870 
(96.7%) patients treated with two antiplatelet drugs, the 
remaining 63 (3.3%) patients were treated with one anti-
platelet and one anticoagulant drug.
Anaemia and risk of bleeding
In the final study population of 2837 patients, a total 
of 93 (3.3%) had a bleeding requiring hospitalisa-
tion within 3 years from baseline. The mean follow- up 
was 1035 days (2.8 years). Patients with anaemia had 
a significantly higher proportion of bleeding events 
(5.8%; 95% CI 3.55% to 8.07%) compared with patients 
without anaemia (2.9%; 95% CI 2.19% to 3.52%). The 
3- year cumulative incidence is illustrated in figure 1A. 
The majority of bleeding events were gastrointestinal 
bleeding (87.1%), while the remaining were cerebral 
bleeding (8.6%) and urogenital bleeding (4.3%). The 
results of the unadjusted and adjusted Cox regression 
analyses are shown in figure 2. The unadjusted analysis 
showed a twofold significant increased risk of bleeding 
in patients with anaemia compared with patients without 
anaemia (HR 2.18; 95% CI 1.37 to 3.48; P <0.001). After 
multivariable adjustment, the risk of bleeding remained 
significantly increased in patients with anaemia (HR 1.69; 
95% CI 1.04 to 2.73; P 0.033). Age was the only covariate 
with a significant impact on bleeding, where an increased 
risk of bleeding was observed in patients aged 70 years 
and above.
Anaemia and risk of ACS and fatal ACS
In the follow- up period of 3 years from baseline, 213 
(7.5%) patients had ACS including fatal ACS. The mean 
follow- up was 1013 days (2.7 years). Throughout the 
3 years, patients with anaemia had a significantly higher 
cumulative incidence at 10.6% (95% CI 7.68% to 13.63%) 
compared with patients without anaemia (7.0%; 95% CI 
5.94% to 7.97%), as illustrated in figure 1B. In figure 3, 
the results of the unadjusted and adjusted Cox regression 
analyses are shown. Patients with anaemia compared with 
patients without anaemia had a significantly increased 
risk of ACS (HR 1.65; 95% CI 1.18 to 2.30; P 0.003). 
When adjusting for multiple covariates, the risk of ACS 
remained significantly increased in patients with anaemia 
(HR 1.47; 95% CI 1.04 to 2.10; P 0.031). Diabetes was the 
only confounder with a significant impact on ACS.
Anaemia and risk of all-cause mortality
A total of 185 (6.5%) patients died within 3 years from base-
line. The mean follow- up was 1057 days (2.9 years). The 
main cause of death was cardiovascular disease (46.5%) 
followed by cancer (25.9%) (online supplemental appendix 
5). Patients with anaemia had a significantly higher mortality 
rate at 18.1% (95% CI 14.4% to 21.9%) compared with 
patients without anaemia (4.5%; 95% CI 3.7% to 5.4%). In 
figure 1C, the Kaplan- Meier survival probability is illustrated 
Figure 1 P values indicate the difference between patients 
with and without anaemia and are based on an unadjusted 
Cox regression model. Numbers at risk are presented below 
the figures. (A) Cumulative incidence of bleeding during 
the 3 years of follow- up, among patients with and without 
anaemia. (B) Cumulative incidence of acute coronary 
syndrome (ACS) and fatal ACS during the 3 years of follow- 
up, among patients with and without anaemia. (C) Kaplan- 
Meier chart of probability of survival during the 3 years of 
follow- up, among patients with and without anaemia.
Figure 2 HR for 3- year bleeding associated with anaemia 
in patients with stable angina treated with percutaneous 
coronary intervention.
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with diverging curves throughout all 3 years of follow- up, 
showing a distinct decrease in survival probability in patients 
with anaemia. The results of the unadjusted and adjusted 
Cox regression analyses are shown in figure 4. The unad-
justed analysis revealed a fourfold significant increased risk 
of all- cause mortality in patients with anaemia compared with 
patients without anaemia (HR 4.33; 95% CI 3.23 to 5.81; P 
<0.001). This remained significant when adjusting for covar-
iates, with a more than twofold increased risk of all- cause 
mortality in patients with anaemia (HR 2.41; 95% CI 1.76 to 
3.30; P <0.001). Covariates with a significant impact on all- 
cause mortality were age, renal insufficiency, COPD, heart 
failure, cancer, peripheral vascular disease, diabetes and 
peptic ulcer.
Additional analyses
To test the strength of the results, additional analyses 
were performed. Analysis on a subgroup including only 
patients with anaemia was performed (n=414). First, 
the association between bleeding requiring hospitalisa-
tion and increasing age, renal insufficiency, peptic ulcer 
and cancer was determined (see online supplemental 
appendix 8). Second, the association between ACS and 
increasing age, renal insufficiency, chronic heart failure, 
peripheral vascular disease, cerebral vascular disease, 
diabetes and cancer was determined (see online supple-
mental appendix 9). Third, the association between all- 
cause mortality and increasing age, renal insufficiency, 
chronic heart failure, peripheral vascular disease, cere-
bral vascular disease, COPD, diabetes and cancer was 
determined (see online supplemental appendix 10).
DISCUSSION
In this Danish cohort study of patients with SA undergoing 
PCI, we investigated the association between anaemia 
and bleeding, ACS and mortality in a long- term follow- up 
period of 3 years. Anaemia was present in 14.6% of the 
entire study population and associated with a significant 
increased risk of bleeding. Furthermore, an increased 
risk of ACS in patients with anaemia was present, and 
anaemia was highly associated with all- cause mortality. 
Thus, along with other studies, our results confirm that 
anaemia was an independent predictor of bleeding, ACS 
and mortality in patients with SA undergoing PCI, even 
after adjusting for covariates.
Identification of factors associated with significant 
complications in the treatment of SA is clearly important 
in a disease that has a relatively low frequency of major 
cardiac adverse events, and in which invasive treat-
ment with PCI offers just symptomatic treatment in the 
majority of cases.23 For some patients, an invasive treat-
ment may even cause more harm than benefit. We have 
determined that bleeding complications requiring hospi-
talisation following treatment with PCI in these patients 
were significantly associated with anaemia. This associ-
ation has previously only been found in a study investi-
gating in- hospital bleeding.24 Hence, this study is, to our 
knowledge, the first to present anaemia as a predictor of 
bleeding following elective PCI in the longer term. Our 
results are also consistent with findings of studies exam-
ining anaemia as a predictor of bleeding in all patients 
undergoing PCI, including patients with ACS.11–16 We 
measured bleeding events requiring hospitalisation, 
meaning that bleeding events were notable and could be 
considered major. In addition, we also revealed a signifi-
cant association between anaemia and an increased risk 
of ACS and all- cause mortality, which is consistent with 
Figure 3 HR for 3- year acute coronary syndrome and 
fatal acute coronary syndrome associated with anaemia 
in patients with stable angina treated with percutaneous 
coronary intervention. COPD, chronic obstructive pulmonary 
disease.
Figure 4 HR for 3- year all- cause mortality associated 
with anaemia in patients with stable angina treated with 
percutaneous coronary intervention. COPD, chronic 
obstructive pulmonary disease.
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previous studies.25–27 The relationship between bleeding, 
ACS and death is complicated with many factors. Poten-
tial mechanisms may include an increased rate of ACS 
after premature cessation of antiplatelet therapy, but 
we can only speculate on actual mechanisms. Previous 
studies have already found bleeding to be associated 
with increased risk of mortality following PCI,9 10 28 which 
might be related to recurrent myocardial infarction and 
complications following recurrent myocardial infarction, 
such as heart failure and arrhythmias. Thus, it is plausible 
that bleeding requiring hospitalisation may increase the 
risk of further complications following PCI. Predicting 
a considerable bleeding risk prior to elective or ad hoc 
PCI by the means of a haemoglobin measurement is of 
great value and should modify our treatment strategies to 
more frequent use of medical therapy in these high- risk 
patients with relatively small reductions in haemoglobin.
In this study population, patients from Danish national 
registers were included. Although patients missing a 
haemoglobin measurement were excluded, characteristics 
of patients with and without a haemoglobin measurement 
were mainly comparable, increasing the generalisability 
of the study to a nationwide level. In addition, only few 
other exclusion criteria were present, reflecting the real- 
world population of patients with SA undergoing PCI. In 
contrast, the majority of previous randomised controlled 
trials tend to exclude older patients and patients with 
severe comorbidities, creating a selective population with 
considerable differences from this real- world popula-
tion. Only one previous study has investigated conserva-
tive treatment versus PCI in patients aged 75 or older.29 
Consistent with other trials, the benefits of PCI found in 
the study of the elderly were limited to a relief in symp-
toms and improvement in QoL.3–6 8 29 30 The Objective 
Randomised Blinded Investigation with optimal medical 
Therapy of Angioplasty in stable angina (ORBITA) trial 
compared for the first time PCI with placebo (sham 
procedure) in patients with SA, and powered to detect a 
relatively modest 16.6 s change in exercise time. ORBITA 
found no significant difference in exercise time.7 Despite 
its several limitations, ORBITA raises questions about the 
efficacy of PCI over medical therapy for symptom control 
in patients with SA. Although this finding was limited by 
a short follow- up time of 6 weeks, the significant benefits 
of medical therapy that was initiated in both groups were 
likely responsible for the non- significant difference in 
exercise time. These studies highlight that in an elderly 
population with baseline anaemia we do have viable alter-
natives to invasive treatments.
Compared with patients without anaemia, we found 
that patients with anaemia were older and had a greater 
proportion of comorbidities, which is similar to results 
from previous studies.11 12 16 24–26 31 However, after adjust-
ment, anaemia continued having a significant associ-
ation with all endpoints. Most randomised trials in SA 
investigating the effect of PCI have historically excluded 
older patients with more frequent comorbidities, high-
lighting the limited knowledge we have for the optimal 
management strategy for these high- risk patients with 
anaemia reflected in our data. Based on the results of 
this study, it is undeniable that patients with anaemia and 
SA deserve more attention, as they are at a higher risk of 
adverse outcomes when treated with PCI, and that PCI 
procedure in these patients may be more harmful than 
beneficial.
Study limitations
Some limitations should be considered. Due to an obser-
vational design, our results should be interpreted only 
as associative and not causal relations. Unmeasured 
confounders could still be present in our study, despite 
using Danish registers to include information on different 
potential confounders for adjustment purposes. Details 
from PCI procedures were not available, including infor-
mation about the degree of stenosis. No data on how long 
patients were treated with antithombotic medicine were 
available. A control group with patients being conserva-
tively treated with medicine alone was also not available, 
as it was very difficult to accurately define patients with 
SA not treated with revascularisation from the available 
registry sources. Additionally, it is unknown whether 
anaemia was persistent or transient throughout follow- up, 
as haemoglobin levels were only measured before base-
line. Furthermore, we were not able to identify patients 
receiving blood transfusion prior to PCI, since data of 
blood transfusion were not available. Due to small popu-
lation size and thus relatively few bleeding events, we were 
unable to comment on the aetiology of anaemia, and 
whether different aetiologies had a different effect on the 
outcomes following PCI. No quantification of bleeding 
severity was available, therefore, we chose to analyse clini-
cally significant bleeding events that required hospitalisa-
tion. Finally, most of the population in Denmark consists 
of a white Caucasian population, and generalisation of 
these data to other racial and ethnic groups should be 
cautioned.
Clinical implications
Although no comparison group of medically treated SA 
was available, we demonstrated a higher bleeding risk 
among patients with anaemia undergoing PCI. Given 
evidence suggesting no benefit of PCI for SA7 8 on hard 
endpoints and only limited benefit for symptom relief, 
our study suggests that in patients with greater risk for 
harm than benefit, that is, patients who are older and 
with anaemia, medical therapy should be seen as a viable 
alternative. These observational data warrant prospective 
and randomised research to further elucidate this issue.
CONCLUSION
Anaemia in patients with SA was significantly associated 
with bleeding, ACS and all- cause mortality following PCI.
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